Side effects with inhaled corticosteroids: the physician's perception
UMass Chan Affiliations
Department of Medicine, Division of Pulmonary, Allergy, and Critical CareDocument Type
Journal ArticlePublication Date
2006-07-15Keywords
Administration, InhalationAdult
Asthma
Attitude of Health Personnel
Child
Glucocorticoids
Humans
Metered Dose Inhalers
Life Sciences
Medicine and Health Sciences
Metadata
Show full item recordAbstract
The National Asthma Education and Prevention Program 1997 guidelines and 2002 update provide an overview of potential local and systemic side effects associated with inhaled corticosteroids (ICS) and suggest ways of minimizing the risk of these side effects occurring. Despite the guidelines and extensive clinical experience of the safe use of ICS, a significant number of physicians retain concerns regarding side effects. Local side effects may lead to patients discontinuing therapy, with or without the knowledge of their physicians. In particular, concerns regarding systemic side effects, such as growth retardation in children and osteoporosis, remain relatively widespread. Pharmacokinetic studies reveal that different ICS compounds and formulations result in different degrees of systemic bioavailability, indicating possible differences in their potential to cause systemic side effects. However, clinical studies that can be used to differentiate between ICS formulations are generally lacking. Consequently, there is a need to continue to further our understanding of side effects with ICS, with the aim of identifying formulations, devices, and doses with an optimal risk/benefit ratio. The introduction of new agents with potentially improved safety profiles may reassure physicians and patients as to the relative benefits of ICS therapy in asthma.Source
Chest. 2006 Jul;130(1 Suppl):41S-53S. Link to article on publisher's siteDOI
10.1378/chest.130.1_suppl.41SPermanent Link to this Item
http://hdl.handle.net/20.500.14038/41225PubMed ID
16840367Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1378/chest.130.1_suppl.41S